# VLP Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vlp-therapeutics

- Industry: Healthcare
- Headquarters: Gaithersburg, US
- Website: www.vlptherapeutics.com
- Total disclosed funding: $37M
- Latest round: Series A (Dec 27, 2021)
- Investors on record: 7

## About

VLP Therapeutics, Inc., based in the US, specializes in creating innovative vaccines utilizing virus-like particles to combat infectious diseases, including dengue fever and SARS-CoV-2.Founded in 2013, VLP Therapeutics, Inc. is headquartered in Gaithersburg, US, and is focused on advancing vaccine development through a proprietary platform. The company was co-founded by Kei Tolliver and Misako Nakata, who have extensive backgrounds in biotechnology. VLP Therapeutics has successfully completed 4 deals, with its most recent funding round being a Series A that raised USD 21.00 mn in November 2023, backed by investors including MUFG Bank, Miyako Capital, Nobelpharma, SK Impact Fund, and Sojitz. This round brings the total amount raised by the company to USD 21.00 mn.VLP Therapeutics, Inc. specializes in innovative vaccine technologies, focusing on a proprietary platform known as i-aVLP. This technology employs virus-like particles (VLPs) to develop vaccines targeting infectious diseases, including a tetravalent dengue virus-like particle-based (DENVLP) vaccine and a self-amplifying RNA vaccine, both of which have progressed through preclinical and clinical testing phases. The vaccines are designed to reduce disease prevalence and enhance global public health. The company serves a wide range of clients, including research institutions, healthcare providers, and government health organizations across Japan, the United States, and regions in Southeast Asia where dengue fever is prevalent.VLP Therapeutics generates revenue through strategic partnerships and funding arrangements, highlighted by a recent investment of 885 million yen (approximately USD 6.00 mn) from the Global Health Innovative Technology (GHIT) Fund. The company’s revenue model is primarily derived from collaborative agreements with academic and governmental entities that support vaccine development projects, including funding for clinical trials and multi-year research agreements. As a result, revenue may stem from grants, investments, and partnerships aimed at enhancing the company’s research capabilities and product offerings within the global vaccine market.VLP Therapeutics plans to leverage its recent funding of USD 21.00 mn raised in November 2023 to address public health challenges by disseminating innovative vaccines both domestically and internationally. The company is focusing on expanding its vaccine offerings and aims to explore new markets, potentially targeting regions where infectious diseases are prevalent. These initiatives are expected to enhance its presence in the global vaccine market while addressing pressing health issues.

## Funding rounds

- Series A, Dec 27, 2021, $21M — MUFG Bank, Sojitz Corporation, Miyako Capital, SK Impact Fund, Nobelpharma
- Series A, Mar 15, 2021, $16M — Sojitz Corporation, Miyako Capital, SK Impact Fund, Konishiyasu Co., Ltd., RJ Fund, LLC

## Investors

- Sojitz Corporation — Series A
- Miyako Capital (https://capitalatlas.ai/funds/miyako-capital) — Series A
- SK Impact Fund — Series A
- Konishiyasu Co., Ltd. — Series A
- RJ Fund, LLC — Series A
- MUFG Bank — Series A
- Nobelpharma — Series A